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Abstract: Spirotetronates are actinomyces-derived polyketides that possess complex structures and
exhibit potent and unexplored bioactivities. Due to their anticancer and antimicrobial properties,
they have potential as drug hits and deserve further study. In particular, abyssomicin C and tetrocarcin
A have shown significant promise against antibiotic-resistant S. aureus and tuberculosis, as well
as for the treatment of various lymphomas and solid tumors. Improved synthetic routes to these
compounds, particularly the class II spirotetronates, are needed to access sufficient quantities for
structure optimization and clinical applications.
Keywords: natural product; spirotetronate; antibiotic; anticancer; drug resistance; Diels-Alder;
Diels-Alderase; biosynthesis; total synthesis; Bcl-2 inhibitor; pABA inhibitor; UPR apoptosis
1. Introduction
It has been estimated that every milliliter of seawater contains about 1 million bacteria [1–4].
To thrive in such a competitive environment, microbes need to produce secondary metabolites,
also referred to as natural products, which primarily serve to regulate bacterial communication or
thwart predators. Endowed by a rapid growth rate and an uncanny ability to exchange genetic
material, bacteria constantly evolve. Such a rapid evolution goes hand-in-hand with a highly adaptable
biosynthetic machinery to ensure survival of the fittest [5]. As predators acquire resistance to certain
secondary metabolites, the preyed upon synthesize more sophisticated compounds to ensure their
defense [6,7]. Thus, from a chemistry perspective, the structures of natural products are dynamic
and undergo continuous refinement in order to address the challenges faced by the producing
bacteria [8–10].
In Western medicine, there are numerous examples of bacterial natural products that have been
used as drugs or have become starting points for the development of new drugs [11]. Arguably the
best example is penicillin. Soon after its discovery in 1928 [12], penicillin revolutionized the use
of antibiotics in medicine and led to the development of several drug classes still in use today [13].
Unfortunately, the golden era of antibiotics, sometime between the 1940s and the 1970s, was rather
short-lived as antibiotic resistance started to occur [14–18]. In fact, to-date antibiotic resistance is
responsible for about 23,000 deaths annually in the United States alone, and another 25,000 deaths
in Europe [10,11,19]. Alarmingly, as the number of antibiotic-resistant bacteria has proliferated,
the number of new antibiotics and antibiotic-based research has dwindled. This troubling phenomenon
is a combination of stringent FDA requirements, deprioritization by the pharmaceutical industry
and over-prescription of antibiotics [20]. Similarly to bacterial resistance, cancer cells also become
tolerant and refractory to previously efficacious pharmacological treatment. [21]. These precipitous
developments of multidrug resistance necessitate the need for second-line anticancer drugs [22].
As with antibiotics, marine natural products have played an important role in the development of new
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anticancer strategies with some being adopted clinically [23]. In turn, this has led to an urgent need for
the discovery of new antibiotics from underexplored sources such as marine bacteria [24–28].
In the past decade, natural products have been revisited as viable drug leads [18,19,29–33].
The renewed interest in natural products as drug leads is a combination of the improved ability for
high-throughput screening of natural sources and the failure of combinatorial chemistry to deliver
sufficient numbers of viable drug candidates [34,35]. Among natural products, those derived from
marine sources have been valuable contributors to human health, with many being approved for
clinical application [36,37]. This review seeks to bring attention to the large family of natural products
known as spirotetronates, which have broad potential as pharmaceutical leads.
2. Spirotetronates: Derivation, Classifications, and Biological Relevance
The discovery of chlorothricin (1) in 1969 [38] defined a new class of bacterial metabolites that
possess an architecturally intriguing structure and promising chemotherapeutic properties as antitumor
antibiotics. Referred to as spirotetronates, these compounds are commonly produced by both marine
and terrestrial actinomyces and are structurally identified by the presence of a tetronic acid spiro-linked
to a cyclohexene (or a cyclohexane) ring (Figure 1b, red motif). Spirotetronates can be further divided
into two sub-classes: class I, which contain the spirotetronate motif integrated within a macrocycle and
class II, which also contain an integrated decalin (Figure 1b, blue motif) and frequently, oligosaccharide
chains attached to the decalin and/or the macrocycle (Figure 1b, green circle) [39,40]. Beyond these
general requirements, the structures of class I and II are highly variable (Figure 1).
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Figure 1. (a) Chemical structure of chlorothricin (1) the archetype of the spirotetronate natural products;
(b) General motif of class I and class II spirotetronates; (c) Representative examples of class I (2–4) and
class II (5–7) spirotetronates.
The spirotetronates are prepared by their source organisms for use as antibiotics in interbacterial
warfare. Many have been found to display broad-spectrum activity against Gram-positive
bacteria [41–43]. Some spirotetronates have also been described as effective chemotherapeutic agents
and recently, retroviral reactivators [44,45]. The disparate biological impact of spirotetronates warrants
their exploration as drug candidates. The remainder of this review will focus on the contextualized
recent advances in the fields of class I and II spirotetronates, and how they support the need for
improved access via synthesis.
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3. Class I Marine Spirotetronates
Among the marine class I spirotetronates, none have enjoyed more attention than the
abyssomicins [46]. Originally derived from Verrucosispora maris AB 18-032, abyssomicin C (2) was
isolated from a sediment sample from the Japanese Sea at a depth of 283 m along with two biologically
inactive relatives (abyssomicins B and D) [47]. Named for the extreme depth at which its source resides,
abyssomicin C and many other members of the family have been found to be potent inhibitors of the
para-aminobenzoic acid (pABA) pathway via their action as chorismate mimics [47].
3.1. Biosynthesis
The biosynthesis of all class I spirotetronates begins through a series of iterative chain elongation
steps in type I polyketide synthase (PKSI) by attaching acetyl CoA (8) and/or propanoyl CoA (9) to the
acyl carrier protein (ACP) [48,49]. After reaching the appropriate length (e.g., structure 10), the process
is terminated by a glyceryl-ACP unit [50] to form, after condensation, tetronic acid (11). The tetronic acid
motif then undergoes acetylation-elimination to form butenolide 12 [51]. Intramolecular Diels-Alder
(IMDA) cyclization between the butenolide and the pendant diene yields the general architecture
of the class I spirotetronates (Figure 2a). Recent studies have unveiled an enzyme responsible for
catalyzing the IMDA reaction to produce abyssomicin C (2) [52]. The spirotetronate cyclase, AbyU is a
homodimeric Diels-Alderase found to catalyze the construction of the spirotetronate motif of 2 in one
of its two eight-stranded antiparallel β-barrels [52]. This active site is however not conserved in the
biosynthesis of class II spirotetronates [52].
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Figure 2. (a) Generic biosynthetic pathway for class I spirotetronates; (b) Enzymatic conversion and
postulated biosynthetic relationship of various abyssomicins.
Conversion of abyssomicin 6 (13) to abyssomicin 2 (14) is biosynthetically accomplished by AbmV,
a P450 enzyme responsible for C11-C12 tandem epoxidation and SN2-epoxide opening sequence
(Figure 2b) [53]. Analogous enzymes are proposed to oxidize other abyssomicins but AbmV is the
first isolated enzyme and is relevant to the newly discovered neoabyssomicins [54]. In this case,
a Baeyer-Villiger oxidation at the C7 carbonyl group is postulated to expand the macrocycle and
provide neoabyssomicin B (15) [54]. Neoabyssomicin B could then be enzymatically converted to
neoabyssomicins C and D (through hydrolysis or methanolysis), and neoabyssomicin A (through a
retro-aldol/Michael reaction sequence, Figure 2b) [54]. The enzymatic pathway to these natural
products has yet to be elucidated, presenting opportunities to advance our understanding of the
biosynthesis of this family [55].
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3.2. Synthesis
Class I marine spirotetronates and specifically abyssomicin C (2) have been the subject of
extensive synthetic studies [56–59]. The first synthesis of 2 was executed by the Sorensen group [60].
This daring synthesis features a bioinspired Diels-Alder reaction to convert acyclic tetronate 19 to
spirotetronate 21. Epoxidation of the cyclohexene ring and epoxide-opening then formed abyssomicin
C (2) together with its C7 atropisomer (later identified as atrop-abyssomicin C (32), Figure 3a).
More recently, the Nicolaou group reported an atroposelective synthesis of abyssomicin C [61–63].
Central to this strategy is the construction of spirotetronate motif (24) via a Dieckmann condensation
of 22 [64]. Chain elongation and Grubbs-catalyzed macrocyclization then yielded 2. The observed
atroposelectivity toward 2 was attributed to the stereoselectivity of the macrocyclization (Figure 3b).
These authors also reported that interconversion of abyssomicin C (2) to its atropoisomer (32) can
be accomplished under acidic conditions. The Saicic group also synthesized atrop-abyssomicin C
targeting spirotetronate (28) as the key intermediate [65]. To this end, cyclohexane 25 was converted to
28 under [(PPh3)AuNTf2]-catalysis [66]. Following chain elongation, a Nozaki-Hiyama-Kishi (NHK)
reaction was employed to affect macrocyclization (Figure 3c). This strategy has also been applied to
the synthesis and biological evaluation of various desmethylated versions of abyssomicin C [67].
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(b) The Nicolaou atroposelective synthesis of abyssomicin C and atrop-abyssomicin C (32, Figure 5)
featuring a ring-closing metathesis (RCM); (c) The Saicic synthesis of atrop-abyssomicin C featuring a
Nozaki-Hiyama-Kishi (NHK) macrocyclization.
3.3. Biological Relevance
Abyssomicin C (2) was found to be the first structure-based inhibitor of amino deoxychorismate
synthase (ADCS), an enzyme essential for the conversion of chorismic acid (29) to p-aminobenzoic acid
(pABA, 31). Since the pABA pathway is exclusive to bacteria and essential to their survival, it represents
an attractive target for antibacterial drug design [68,69]. Acting as a structural mimic of 29 (see common
red motif, Figure 4), abyssomicin C binds at the chorismate active site of ADCS where it irreversibly
reacts with a proximal cysteine via conjugate addition at the C9 center (Michael-acceptor) [70].
Unfortunately, this type of conjugate addition reaction is not very selective leading to off-target
complications [71].
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In general, abyssomicins that do not contain the C8–C9 enone functionality are biologically
inactive. An interesting exception is abyssomicin J (35, Figure 5), which is active (MIC = 3.125 µM)
against M. tuberculosis [72]. It has been shown that 35 undergoes P450 oxidation in vitro, followed
by a retro-Michael addition to yield abyssomicin C (2). In turn, this suggests a viable prodrug
strategy for the masking of the Michael acceptor site of abyssomicin C to increase its biological
half-life [72]. In addition, the Saicac group was able to increase the selectivity of atrop-abyssomicin C
for Gram-positive bacteria over HeLa and PMBC (cancerous and healthy) cell lines through global
demethylation and protection of the pendant alcohol as a benzyl ether [67]. Biological evaluation of
this derivative, named atrop-O-benzyl-desmethylabyssomicin C (36), suggests that the methyl groups
of native abyssomicin C play a role in the ligand-binding mode of its mammalian targets, whereas
they are not critical for its antibiotic activity. Combining the properties of abyssomicin J (35) and
atrop-O-benzyl-desmethylabyssomicin C (36) could lead to potent and selective antibiotics.
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Figure 5. Relevant and recent members of the abyssomicin family.
Abyssomicin 2 (34) was discovered as part of a natural products screening campaign to identify
HIV-1 reactivators [45]. It was found that 34 reactivates HIV-1 at 56% at an EC50 of 13.9 µM.
The mechanism of action of abyssomicin 2 is novel and remains to be elucidated. While conducting
this study, the researchers also proposed a structural correction to abyssomicin 1 (33), showing it
to be almost enantiomeric to the originally proposed structure, with the exception of the alcohol
assignment [45]. The retroviral induction potential of abyssomicin 2 (34) demonstrates the family’s
broad application as drug leads, not limited to antitumor antibiotics.
4. Class II Marine Spirotetronates
4.1. Biosynthesis
Class II pirotetronates are synthesized analogously to their class I counterparts (Figure 3). In this
case, however, an intramolecular Diels-Al er (IMDA) produces the decalin moiety of 38 prior to
c ain t rmination of the PKSI and formation of the tetronate of 40 (Figure 6a) [73–76]. Recently
VstJ, the Diels-Alderas responsible for spir tetronate-formation in versipelostatin (43), has been
id ntifi d through com ari on of genes responsibl f r versipelostatin synthesis with those of the
biosynthetic cl ster f chlor thricin, tetrocarcin A, and lobo h rin, ratio alizing conservation of
the biosynthetic pathway [77]. When in ubated with the Diels-Alder precursor 41, VstJ i duced
stereosel ctive formation of 42 (Figure 6b); without VstJ t is cyclization failed to occur [77]. Historically,
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this study provided the first example of conclusive enzymatic involvement in spirotetronate cyclization,
although VstJ remains to be structurally characterized and its precise mechanism of catalysis is
currently unknown.
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Figure 6. (a) General biosynthesis of class II spirotetronates; (b) VstJ-catalyzed intramolecular
Diels-Alder reaction of 41 to 42 en route to versipelostatin A (43).
4.2. Synthesis
To-date no total synthesis of a class II spirotetronate has been achieved. Since most class II family
members contain one or two oligosaccharide chains, synthetic studies ave targeted the synthesis
of their aglycons [78]. On this front, the total syntheses of chlorothricolide (7) [79] and tetronolid
(6) [80–82], the aglycons of chlorothricin (1) a d tetrocarcins (51–54) respectively, have been reporte .
The key st ps toward the synthesis of 6, as accomplished by the Y shii group [80] and later improved
upon by th Roush group [81], are shown in Figure 7. Both strategies feature a biomimetic IMDA
reaction to convert 48 to 49. The Roush approach to perform an IMDA reaction b tween 44 and
45 provided expedi nt access to spirotetr nate motif 47. Coupling f 47 with 49 under Yoshii’s
conditions afforded 50 that underwent macrolactonizati n under Julia coupling conditions to produce
tetronolide (6). Similar strategies were subsequently reported for the synthesis of chlorothricolide
(7) [79]. More recently, the Boeckman group report d an improved 27-step synthesis of tetronolid (6)
using a similar IMDA and Julia-based key steps [82].
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The IMDA reaction is prevalent in almost every synthetic study of class II spirotetronates [81,83,84].
All these efforts toward class II spirotetronate aglycons are too cumbersome to practically bring forward
large quantities of material, and they neglect the oligosaccharide chains, which are essential for
biological activity in all marine-derived class II spirotetronates [85]. No total syntheses of class II
spirotetronates have been accomplished and the field would benefit from updated and more practical
preparations of these natural products.
4.3. Biological Relevance
Tetrocarcin A (51, Figure 8) has been found to effectively inhibit Gram-positive bacteria by
blocking RNA and protein synthesis [86]. In human cells, 51 was found to inhibit the integral
intracellular membrane protein Bcl-2 and activate stress signals in the mitochondria and endoplasmic
reticulum [44,87]. Responsible for the downregulation of caspase-3, which is an effector of mammalian
cell death, Bcl-2 becomes overexpressed on the mitochondrial surface of cancer cells and is responsible
for their anti-apoptotic properties [88–92]. Tetrocarcin A (51) was later found to directly induce
apoptosis in breast cancer cells accompanied by activation of a proteolytic cascade of caspases and
a concomitant decrease in phosphorylation of protein kinase B, pyruvate dehydrogenase kinase-1,
as well as phosphatase and tensin homolog (Akt, PDK-1, and PTEN, respectively) [93]. Recently,
the upstream target of tetrocarcin A (51) was found to be junctional adhesion molecule-A (JAM-A),
a regulator of human epidermal growth factor receptor-2 (HER2) protein expression in breast cancer
cells [94,95]. Downregulation of JAM-A was proposed to lead to inhibition of Bcl-2 and extracellular
signal-regulated kinases (ERK), in turn resulting in suppression of proliferation and caspase-dependent
apoptosis in breast cancer cells (Figure 9) [94]. This most recent study of tetrocarcin A (51) specifically
advocates for its clinical application as a chemotherapy agent.
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Three new members of the lobophorin family have recently been used to trigger cell death in
murine tumor fibroblasts through the apoptotic arm of unfolded protein response [96]. Lobophorins
CR1 (55), CR2 (60), and CR3 (61) were isolated from Streptomyces sp. 7790_N4 from marine sediment in
Costa Rica (Figure 8). Lobophorins CR1 (55) along with known lobophorins A (57), B (58), E and F [97]
(not pictured) were found to induce endoplasmic reticulum (ER) stress leading to PERK-mediated
phosphorylation of eukaryotic initiation factor 2 alpha (elF2α) in oral squamous cell carcinoma.
In turn, this leads to activation of the proapoptotic transcription factors, ATF4 and CHOP, ultimately
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inducing CHOP-dependent apoptosis (Figure 9) [96]. These new members of the lobophorin family
were identified using a screen targeting natural products that induce apoptosis through unfolded
protein-response. Unfortunately, the limited cultivability of these lobophorins prevented the evaluation
of lobophorins CR2 and CR3 [96]. Lobophorin B (58) is nearly identical to kijanimicin (59) [60,98],
lacking an additional glycosylation at the B-sugar. Lobophorins CR2 and CR3 (60, 61) appear to be
allylic oxidation products of 58, suggesting a biosynthetic relationship that merits further exploration.
Additionally, lobophorin K (56) was isolated from Streptomyces sp. M-207 found in marine sediment at
a depth of 1800 m, and was found to have cytotoxic activity against pancreatic carcinoma and breast
adenocarcinoma, as well as moderate and selective antibiotic activity against S. aureus [99].
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Figure 9. Signaling pathways targeted by tetrocarcin A (Tet-A, 51) in breast cancer and recently
discovered lobophorin CR1 (Lob CR1, 55) in oral carcinoma.
Recently three new marine tetrocarcins were discovered. Tetrocarcins N (53) and O (54) were
isolated from Micromonospora sp. 5-297 using a PCR-based screen that targets glycosidic antibiotics [100].
They exhibited antibacterial activity against B. subtilis. Compound 53 was substantially more potent
than 54 suggesting that extended oligosaccharide chains enhance the biological activity. Both 53 and
54 were less active than tetrocarcin A (51), suggesting that the formyl group at the spirotetronate
motif is biologically important [100]. The most recent tetrocarcin to be discovered is tetrocarcin Q (52),
which was isolated from Micromonospora carbonacea LS276 and contains an unusual acetoxy unit on its
oligosaccharide motif [101].
Phocoenamicin (62, Figure 10), a new class II aglycon with an uncommon C11 macrocycle,
was discovered in the intestinal microbiome of a freshly deceased dolphin using a high-throughput
antibacterial screen [102]. Compound 62 possesses potent activity against Clostridium difficile with a
MIC of 2.6 µM compared to vancomycin’s 2.9 µM [102]. The structurally related phocoenamicins B (63)
and C (64) were isolated from Micromonospora sp. and were found to be active against S. aureus [103];
phocoenamicin C (64) was also found to inhibit M. tuberculosis. In parallel to the chlorothricin family,
64 contains a lactone macrocycle that presumably derives from Baeyer-Villiger-type ring expansion of
62 [73]. The oligosaccharide motif of phocoenamicins remains unchanged throughout this family and
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features an unusual chlorosalicyclic ester. The new discovery of phocoenamicins reveals the untapped
depth of the class II spirotetronate family, and their potential as drug leads.Mar. Drugs 2019, 17, x  9 of 15 
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5. Conclusions
In the ongoing public health crises of antibiotic resistance and untreatable cancers, marine
natural products provide inspiration for the development of new drugs [104,105]. Among them,
spirotetronates, products of bacterial warfare, deserve particular attention not only for their exquisite
biosynthesis, but also for their exceptional promise as antitumor antibiotics. In particular the
abyssomicins, representative members of the class I spirotetronate family, have been the subject of
extensive studies related to their biosynthesis, chemical synthesis and mode-of-action. These studies
have demonstrated the significant antibacterial potential of these compounds by targeting the pABA
pathway. Nonetheless, challenges related to their indiscriminate reactivity and target selectivity need
to be overcome before clinical evaluation. Class II spirotetronates are less studied, but many members
have encouraging antibiotic and antitumor activity and interesting but unexplored mode-of-action.
For i stance, tetrocarcin A has been found to interfere with the Bcl2 pathway inducing apoptosis in
cancer cells. The therapeutic relevance of this pathway has been recently demonstrated with Venetoclax,
to-date the only approved drug that targets Bcl2 [106–110]. On the other hand, oligosaccharide chains
attached to a class II aglycon are essential to antibiotic activities. Unfortunately, the overall complexity
of the class II spirotetronates and the recalcitrance of their producers toward large-scale culturing,
severely limits the availability of these compounds for further preclinical and clinical studies. In turn,
this makes particularly significant and timely the development of improved synthetic [111–120] and
biosynthetic strategies [121–126] to access class II spirotetronates. Research along these lines as well as
the continuous exploration of marine bacteria [127–132] will define new paradigms for drug discovery.
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